Levodopa Positively Affects Neovascular Age-Related Macular Degeneration

Anna G. Figueroa, Brennan M. Boyd, Cory A. Christensen, Cameron G. Javid, Brian S. McKay, Timothy C. Fagan, Robert W. Snyder

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Age-related macular degeneration (AMD) is a common cause of blindness worldwide. Neovascular AMD (nAMD) is an advanced form of the disease, in which excess vascular endothelial growth factor (VEGF) induces growth of new blood vessels that leak fluid, accounting for 90% of vision loss in AMD. Dysfunction of the retinal pigment epithelium likely initiates AMD. Retinal pigment epithelial cells express a G protein-coupled receptor, GPR143, which downregulates VEGF in response to levodopa. Anti-VEGF therapy effectively treats nAMD, suggesting that excessive VEGF activity drives the pathology. Methods: In an open-label pilot study, in patients with newly diagnosed nAMD and naïve to anti-VEGF injections (Cohort-1), the effects of carbidopa-levodopa on vision and anatomic outcomes were evaluated for 4 weeks. Then patients were followed 5 months further with ascending levodopa doses. Patients previously treated with anti-VEGF injection therapy (Cohort-2) were also treated with ascending levodopa doses and evaluated for 6 months. Results: Levodopa was safe, well tolerated, and delayed anti-VEGF injection therapy while improving visual outcomes. In the first month, retinal fluid decreased by 29% (P = .02, n = 12) without anti-VEGF treatment. Through 6 months the decrease in retinal fluid was sustained, with a mean frequency of 0.38 injections/month. At month 6, mean visual acuity improved by 4.7 letters in Cohort-1 (P = .004, n = 15) and by 4.8 letters in Cohort-2 (P = .02, n = 11). Additionally, there was a 52% reduction in the need for anti-VEGF injections in Cohort-2 (P = .002). Conclusions: Our findings suggest efficacy and support the pharmacological targeting of GPR143 with levodopa for the treatment of nAMD in future studies.

Original languageEnglish (US)
Pages (from-to)122-128.e3
JournalAmerican Journal of Medicine
Volume134
Issue number1
DOIs
StatePublished - Jan 2021
Externally publishedYes

Keywords

  • Age-related macular degeneration (AMD)
  • Carbidopa-levodopa
  • GPR143
  • L-DOPA
  • Neovascular AMD
  • Prospective study
  • Retinal pigment epithelium
  • Wet AMD
  • nAMD

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Levodopa Positively Affects Neovascular Age-Related Macular Degeneration'. Together they form a unique fingerprint.

Cite this